NCI trials for February

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

NCI trials for February

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

For further information, contact the principal investigator listed.

Phase I – 10114

Phase I Trial of 5-Aza-4′-Thio-2′-Deoxycytidine (Aza-TdC) in Patients with Advanced Solid Tumors

National Cancer Institute Developmental Therapeutics Clinic

Doroshow, James H.

(240) 781-3320

Phase I/II – ADVL1614

A Phase 1/2 Study of VX15/2503 (IND#136181) in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors

COG Phase 1 Consortium

Greengard, Emily G.

(612) 626-2378

Phase I/II – EA9152

A Phase IB/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia

ECOG-ACRIN Cancer Research Group

Palmisiano, Neil David

(215) 503-0432

Phase II – 10100

A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination with Atezolizumab Compared to Atezolizumab Alone in Subjects with Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Platinum-Based Treatment is Not an Option

City of Hope Comprehensive Cancer Center LAO

Quinn, David Ian

(323) 865-3956

Phase II – 10104

A Randomized Phase 2 Study of Cabozantinib in Combination with Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer

University Health Network Princess Margaret Cancer Center LAO

Lheureux, Stephanie

(416) 946-4501 X 2415

Phase II – A091605

A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma

Alliance for Clinical Trials in Oncology

Luke, Jason John

(617) 632-6588

Phase II – AMC-103

A Phase 2 Evaluation of VGX-3100, a Synthetic DNA Immunotherapy Targeting Human Papillomavirus 16 and 18 E6 and E7 Proteins, for Anal High-Grade Squamous Intraepithelial Lesions (HSIL) in HIV-Positive Individuals

AIDS Malignancy Consortium

Wang, Chia-Ching (Jackie)

(415) 476-4082 X 146

Phase II – EA3163

Phase II Randomized Trial of Neo-Adjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation Versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)

ECOG-ACRIN Cancer Research Group

Saba, Nabil F.

(404) 778-1900

Phase II – EAE161

Perfusion CT to Predict Progression-Free Survival and Response Rate in Bevacizumab and Paclitaxel Treatment of Platinum-Resistant Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma

ECOG-ACRIN Cancer Research Group

Lee, Susanna I.

(617) 643-2009

Phase II – S1400K

A Phase II Study of ABBV-399 (Process II) in Patients with C-Met Positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP SUB-STUDY)


Waqar, Saiama Naheed

(314) 362-5737

Phase II – S1702

A Phase II Study of Isatuximab (SAR650984) for Patients with Previously Treated AL Amyloidosis


Scott, Emma Catherine

(503) 494-2398

Phase Other – AALL17B2-Q

Predicting Relapse Based on Deep Single-Cell Phenotyping at Diagnosis

Children’s Oncology Group

Davis, Kara Lynn

(650) 724-8073

Phase Other – ARST17B2-Q

Germline Genetic Landscape of Pediatric Rhabdomyosarcoma

Children’s Oncology Group

Lupo, Philip

(713) 798-2960

NCI Community Oncology Research Program (NCORP) clinical trials:

Phase Other – EAQ162CD

Longitudinal Assessment of Financial Burden in Patients with Colon or Rectal Cancer Treated with Curative Intent

ECOG-ACRIN Cancer Research Group

Kircher, Sheetal Mehta

(312) 695-6180

Phase Other – WF-20817CD

Implementation of Smoking Cessation Services within NCI NCORP Community Sites with Organized Lung Cancer Screening Programs

Wake Forest NCORP Research Base

Foley, Kristie L.

(336) 713-5084


President Joe Biden April 9 announced his FY2022 budgetary plans for ARPA-H—Advanced Research Projects Agency-Health—a federal entity designed to “deliver breakthroughs to find cures for cancer and other diseases.” In his initial White House budget proposal—dubbed skinny budget, or budget-lite—Biden is requesting $6.5 billion to fund ARPA-H.  “The discretionary request calls for $6.5 billion to...